Adding smartphone-based cognitive-behavior therapy to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled trial
Year: 2015
Type: article
Study design: Study Protocol
Abstract: BACKGROUND: Major depression is one of the most debilitating diseases in terms of quality of life. Less than half of patients suffering from depression can achieve remission after adequate antidepressant treatment. Another promising treatment option is cognitive-behavior therapy (CBT). However, the need for experienced therapists and substantive dedicated time prevent CBT from being widely disseminated. In the present study, we aim to examine the effectiveness of switching antidepressants and starting a smartphone-based CBT program at the same time, in comparison to switching antidepressants only, among patients still suffering from depression after adequate antidepressant treatment. METHODS/DESIGN: A multi-center randomized trial is currently being conducted since September 2014. The smartphone-based CBT program, named the "Kokoro-App," for major depression has been developed and its feasibility has been confirmed in a previous open study. The program consists of an introduction, 6 sessions and an epilogue, and is expected to be completed within 9 weeks by patients. In the present trial, 164 patients with DSM-5 major depressive disorder and still suffering from depressive symptoms after adequate antidepressant treatment for more than 4 weeks will be allocated to the Kokoro-App plus switching antidepressant group or the switching antidepressant alone group. The participants allocated to the latter group will receive full components of the Kokoro-App after 9 weeks. The primary outcome is the change in the total score on the Patient Health Questionnaire through the 9 weeks of the program, as assessed at week 0, 1, 5 and 9 via telephone by blinded raters. The secondary outcomes include the change in the total score of the Beck Depression Inventory-II, change in side effects as assessed by the Frequency, Intensity and Burden of Side Effects Rating, and treatment satisfaction. DISCUSSION: An effective and reachable intervention may not only lead to healthier mental status among depressed patients, but also to reduced social burden from this illness. This paper outlines the background and methods of a trial that evaluates the possible additive value of a smartphone-based CBT program for treatment-resistant depression. TRIAL REGISTRATION: UMIN-CTR: UMIN000013693 (registered on 1 June 2014).
Source: Trials
Institutions: National Center of Neurology and Psychiatry, National Center Hospital of Neurology and Psychiatry, Translational Medical Center, National Center of Neurology and Psychiatry, National Center for Cognitive Behavior Therapy and Research, National Institute of Mental Health, University of Kochi, Kōchi University, Nagoya City University, Okayama University Hospital, Kyoto University
Language: English
Subfield: Applied Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $2,790
Funders: Eli Lilly and Company, Pfizer, GlaxoSmithKline, GlaxoSmithKline Japan, Meiji Seika Pharma, Astellas Pharma, Shionogi, Otsuka Pharmaceutical, Japanese Society of Clinical Pharmacology and Therapeutics, National Center of Neurology and Psychiatry, Mitsubishi Tanabe Pharma Corporation, Pfizer Japan, Chugai Pharmaceutical, MSD K.K., Eli Lilly Japan, Japan Society for the Promotion of Science, Janssen Pharmaceuticals
OpenAlex ID: W1946968708
